keyword
MENU ▼
Read by QxMD icon Read
search

Ledipasvir

keyword
https://www.readbyqxmd.com/read/27913920/ns5a-resistance-associated-variants-undermine-the-effectiveness-of-ledipasvir-and-sofosbuvir-for-cirrhotic-patients-infected-with-hcv-genotype-1b
#1
Eiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, Kazufumi Dohmen, Nobuhiko Higashi, Kazuhiro Takahashi, Akira Kawano, Koichi Azuma, Takeaki Satoh, Makoto Nakamuta, Toshimasa Koyanagi, Masaki Kato, Shinji Shimoda, Eiji Kajiwara, Jun Hayashi
BACKGROUND: Little real-world cohort data has been reported for Asians who have received interferon-free regimens with sofosbuvir (SOF) for chronic hepatitis C virus (HCV) infection. We evaluated the effectiveness and safety in clinical practice of ledipasvir (LDV) plus SOF for Japanese patients infected with HCV genotype 1. METHODS: This large, multicenter, real-world cohort study consisted of 772 patients treatment-naive or -experienced, with or without compensated cirrhosis, who were treated with LDV (90 mg)/SOF (400 mg) for a fixed 12-week duration...
December 2, 2016: Journal of Gastroenterology
https://www.readbyqxmd.com/read/27910116/the-cost-effectiveness-of-testing-for-ns5a-resistance-associated-polymorphisms-at-baseline-in-genotype-1a-infected-treatment-na%C3%A3-ve-and-treatment-experienced-subjects-treated-with-all-oral-elbasvir-grazoprevir-regimens-in-the-united-states
#2
E H Elbasha, M N Robertson, C Nwankwo
BACKGROUND: The presence of baseline NS5A resistance-associated variants (RAVs) impacted treatment response in HCV genotype 1a (GT1a)-infected patients treated with elbasvir/grazoprevir (EBR/GZR) for 12 weeks, but not patients treated with EBR/GZR and ribavirin (RBV) for 16 weeks. AIM: We assessed the cost-effectiveness of baseline testing for NS5A RAVs in EBR/GZR-treated patients compared without testing and with current treatments for GT1a patients. METHODS: We simulated the course of treatment with EBR/GZR, ledipasvir/sofosbuvir (LDV/SOF) and ombitasvir/paritaprevir/ritonavir+dasabuvir (3D) with or without RBV and natural history of disease of GT1a patients...
December 1, 2016: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27895394/concise-review-interferon-free-treatment-of-hepatitis-c-virus-associated-cirrhosis-and-liver-graft-infection
#3
REVIEW
Nina Weiler, Stefan Zeuzem, Martin-Walter Welker
Chronic hepatitis C is a major reason for development of cirrhosis and hepatocellular carcinoma and a leading cause for liver transplantation. The development of direct-acting antiviral agents lead to (pegylated) interferon-alfa free antiviral therapy regimens with a remarkable increase in sustained virologic response (SVR) rates and opened therapeutic options for patients with advanced cirrhosis and liver graft recipients. This concise review gives an overview about most current prospective trials and cohort analyses for treatment of patients with liver cirrhosis and liver graft recipients...
November 7, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27882839/real-world-drug-costs-of-treating-hepatitis-c-genotypes-1-4-with-direct-acting-antivirals-initiating-treatment-at-fibrosis-0-2-and-3-4
#4
Timothy A Bach, Kathy Zaiken
BACKGROUND: Direct-acting antivirals (DAA) for the treatment of hepatitis C virus (HCV) have drastically improved outcomes but are also very costly. For this reason, priority for treatment is often given to patients with a higher fibrosis score at baseline by payers and providers rather than treating all eligible patients. Simulation studies have suggested that waiting to treat patients until fibrosis 3-4 may be more costly and result in worse outcomes; however, real-world implications are unknown...
December 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27882706/high-frequency-of-potential-interactions-between-direct-acting-antivirals-and-concomitant-therapy-in-hiv-hepatitis-c-virus-coinfected-patients-in-clinical-practice
#5
J Macías, P Monge, M Mancebo, N Merchante, K Neukam, L M Real, J A Pineda
OBJECTIVES: The aim of the study was to analyse the frequency and degree of potential drug-drug interactions (DDIs) between direct-acting antivirals (DAAs) and concomitant medication used by HIV/hepatitis C virus (HCV)-coinfected patients, including antiretroviral therapy (ART) and other drugs. METHODS: All patients with HIV infection and viraemic HCV genotype 1, 3 or 4 coinfection attending a tertiary care centre in Spain (November 2014 to November 2015) were included in the study...
November 24, 2016: HIV Medicine
https://www.readbyqxmd.com/read/27875005/asunaprevir-daclatasvir-and-sofosbuvir-ledipasuvir-for-recurrent-hepatitis-c-following-living-donor-liver-transplantation
#6
Kiyohiko Omichi, Nobuhisa Akamatsu, Kazuhiro Mori, Junichi Togashi, Junichi Arita, Junichi Kaneko, Kiyoshi Hasegawa, Yoshihiro Sakamoto, Norihiro Kokudo
AIM: This study aimed to clarify the efficacy and safety of interferon-free therapy using asunaprevir and daclatasvir, or sofosbuvir and ledipasuvir for post living donor liver transplantation (LDLT) recipients with hepatitis C virus (HCV). METHODS: A retrospective cohort study of LDLT recipients with HCV genotype 1b treated with asunaprevir (100 mg twice daily) and daclatasvir (60 mg once daily), or sofosbuvir (400 mg/day) and ledipasvir (90 mg/day) was conducted...
November 22, 2016: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/27872683/safe-and-effective-sofosbuvir-based-therapy-in-patients-with-mental-health-disease-on-hepatitis-c-virus-treatment
#7
Lydia Shuk Yee Tang, Jack Masur, Zayani Sims, Amy Nelson, Anu Osinusi, Anita Kohli, Sarah Kattakuzhy, Michael Polis, Shyam Kottilil
AIM: To study impact of baseline mental health disease on hepatitis C virus (HCV) treatment; and Beck's Depression Inventory (BDI) changes with sofosbuvir- and interferon-based therapy. METHODS: This is a retrospective cohort study of participants from 5 studies enrolled from single center trials conducted at the Clinical Research Center of the National Institutes of Health, Bethesda, MD, United States. All participants were adults with chronic HCV genotype 1 infection and naïve to HCV therapy...
November 8, 2016: World Journal of Hepatology
https://www.readbyqxmd.com/read/27869323/comparative-treatment-effectiveness-of-direct-acting-antiviral-regimens-for-hepatitis-c-data-from-the-veterans-administration
#8
D S Fox, J J McGinnis, I Tonnu-Mihara, J S McCombs
BACKGROUND AND AIMS: Data addressing real world effectiveness of direct acting antiviral agents in hepatitis C infected patients are now emerging. This study compared the sustained virologic response rates achieved 12 weeks post-treatment in patients treated with three such agents by the Veterans Health Administration. METHODS: A retrospective cohort study was conducted using patients who terminated treatment by July 1, 2015. Data were retrieved from the Veterans Health Administration electronic medical records system...
November 21, 2016: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/27868140/psoriasis-as-a-manifestation-of-an-immune-reconstitution-in-two-patients-with-hepatitis-c-treated-with-ledipasvir-sofosbuvir
#9
Franz Heppt, Michael Sticherling
is missing (Short communication).
November 21, 2016: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/27861337/the-levels-of-monoamine-neurotransmitters-and-measures-of-mental-and-emotional-health-in-hcv-patients-treated-with-ledipasvir-ldv-and-sofosbuvir-sof-with-or-without-ribavirin-rbv
#10
Pegah Golabi, Elzafir Elsheikh, Azza Karrar, James M Estep, Issah Younossi, Maria Stepanova, Lynn Gerber, Zobair M Younossi
Mental and emotional health (MEH) impairment is commonly encountered in hepatitis C patients. Although the exact mechanism remains unknown, alterations in neurotransmitter and cytokine levels maybe associated with hepatitis C virus (HCV)-related MEH issues.The aim of the study was to assess association of serum biomarkers with self-reports of MEH in HCV patients before treatment and after achieving sustained virologic response (SVR).The HCV genotype-1-infected patients who achieved SVR at 12 weeks after treatment with ledipasvir (LDV)/sofosbuvir (SOF) ± ribavirin (RBV) were selected...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27848256/successful-ledipasvir-sofosbuvir-treatment-of-active-synovitis-in-a-rheumatoid-arthritis-patient-with-hepatitis-c-virus-related-mixed-cryoglobulinemia
#11
Tomohiro Koga, Shin-Ya Kawashiri, Kazuhiko Nakao, Atsushi Kawakami
No abstract text is available yet for this article.
November 16, 2016: Modern Rheumatology
https://www.readbyqxmd.com/read/27846791/clinical-experience-with-dolutegravir-abacavir-lamivudine-in-hiv-hcv-co-infected-patients-treated-with-a-sofosbuvir-based-regimen-safety-and-efficacy
#12
Tamara M Johnson, Raymund Sison, James P Fallon, Prerak P Shukla, Sristi Bhattarai, Herbert Galang, Richard Habeeb, Jihad Slim
BACKGROUND: There is no known reason to suspect an adverse drug interaction between dolutegravir-based antiretroviral therapy and sofosbuvir, simeprevir, or ledipasvir. There is a paucity of clinical data for this combination. METHODS: Prospective, open-label study of patients with HIV well controlled on dolutegravir, abacavir, and lamivudine, who were co-infected with HCV genotype 1, and required therapy with simeprevir plus sofosbuvir or sofosbuvir/ledipasvir single-tablet regimen (STR) for 12 weeks...
November 2016: HIV Clinical Trials
https://www.readbyqxmd.com/read/27832030/eight-weeks-treatment-with-sofosbuvir-ledipasvir-in-a-4-year-old-child-with-chronic-hepatitis-c-virus-genotype-1-infection
#13
Hagen Graf Einsiedel, Holger Christiansen, Johannes Wiegand
No abstract text is available yet for this article.
December 2016: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/27813162/do-directly-acting-antiviral-agents-for-hcv-increase-the-risk-of-hepatic-decompensation-and-decline-in-renal-function-results-from-erchives
#14
A A Butt, Y Ren, K Marks, O S Shaikh, K E Sherman
BACKGROUND: Directly acting antiviral agents (DAA) have been associated with hepatic decompensation, especially in patients with pre-treatment cirrhosis, but this risk is not well defined. AIM: To determine the incidence of hepatic decompensation, liver transplantation, death and worsening renal function in patients treated with a Paritaprevir/ritonavir, Ombitasvir, Dasabuvir (PrOD), sofosbuvir/simeprevir or sofosbuvir/ledipasvir regimen. METHODS: We followed ERCHIVES participants treated with the above regimens for up to 12 weeks post-treatment...
January 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27810652/alcohol-use-and-hepatitis-c-virus-treatment-outcomes-among-patients-receiving-direct-antiviral-agents
#15
Judith I Tsui, Emily C Williams, Pamela K Green, Kristin Berry, Feng Su, George N Ioannou
BACKGROUND: It is unclear whether alcohol use negatively impacts HCV treatment outcomes in the era of direct antiviral agents (DAAs). We aimed to evaluate the associations between current levels of drinking and treatment response among persons treated for HCV with DAAs in the national Veterans Affairs (VA) healthcare system. METHODS: We identified patients who initiated HCV DAAs over 18 months (1/1/14-6/30/15) and had documented alcohol screening with the Alcohol Use Disorders Identification Test Consumption (AUDIT-C) questionnaire within one year prior to initiating therapy...
October 22, 2016: Drug and Alcohol Dependence
https://www.readbyqxmd.com/read/27806815/new-direct-acting-antiviral-agents-for-the-treatment-of-hepatitis-c-2016-and-beyond
#16
Muhammad Umar, Tayyab Saeed Akhter
Hepatitis C is one of the commonest public health problems with 130 million people infected worldwide and the burden is increasing. Previously, Interferon along with Ribavirin was the mainstay of treatment but it was associated with toxic side effects. An all-oral regimen with higher rates of sustained viral response (SVR), minimal side effects and no restriction for liver fibrosis staging, was long awaited. Several all-oral interferon-free direct acting antiviral agents (DAAs) have now been approved by FDAfor different genotypes of HCV...
October 2016: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
https://www.readbyqxmd.com/read/27804195/the-value-of-cure-associated-with-treating-treatment-na%C3%A3-ve-chronic-hepatitis-c-genotype-1-are-the-new-all-oral-regimens-good-value-to-society
#17
Zobair M Younossi, Haesuk Park, Douglas Dieterich, Sammy Saab, Aijaz Ahmed, Stuart C Gordon
BACKGROUND & AIMS: All-oral regimens are associated with high cure rates in hepatitis C virus-genotype 1 (HCV-GT1) patients. Our aim was to assess the value of cure to the society for treating HCV infection. METHODS: Markov model for HCV-GT1 projected long-term health outcomes, life years, and quality-adjusted life years (QALYs) gained. The model compared second-generation triple (sofosbuvir+pegylated interferon+ribavirin [PR] and simeprevir+PR) and all-oral (ledipasvir/sofosbuvir and ombitasvir+paritaprevir/ritonavir+dasabuvir±ribavirin) therapies with no treatment...
November 2, 2016: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/27799966/recommendations-for-the-clinical-management-of-hepatitis-c-in-iran-a-consensus-based-national-guideline
#18
REVIEW
Seyed Moayed Alavian, Behzad Hajarizadeh, Kamran Bagheri Lankarani, Heidar Sharafi, Nasser Ebrahimi Daryani, Shahin Merat, Minoo Mohraz, Masoud Mardani, Mohamad Reza Fattahi, Hossein Poustchi, Mehri Nikbin, Mahmood Nabavi, Peyman Adibi, Masood Ziaee, Bita Behnava, Mohammad Saeid Rezaee-Zavareh, Massimo Colombo, Hatef Massoumi, Abdul Rahman Bizri, Bijan Eghtesad, Majid Amiri, Ali Namvar, Khashayar Hesamizadeh, Reza Malekzadeh
CONTEXT: Hepatitis C virus (HCV) infection is a major public health issue worldwide, including Iran. The new direct-acting antiviral agents (DAAs) with high efficacy have changed the landscape of HCV treatment. This guideline provides updated recommendations for clinical management of HCV infection in Iran. EVIDENCE ACQUISITION: The recommendations of this guideline are based on international and national scientific evidences and consensus-based expert opinion. Scientific evidences were collected through a systematic review of studies that evaluated efficacy and safety of DAA regimens, using PubMed, Scopus and Web of Science...
August 2016: Hepatitis Monthly
https://www.readbyqxmd.com/read/27797596/pharmacokinetics-and-pharmacodynamics-of-sofosbuvir-and-ledipasvir-for-the-treatment-of-hepatitis-c
#19
Francisca Cuenca-Lopez, Antonio Rivero, Antonio Rivero-Juárez
The sofosbuvir (SOF) plus ledipasvir (LDV) fixed dose combination is the first direct action antiviral (DAA) single-treatment regimen (STR) to be commercialized. It is approved for the treatment of Hepatitis C virus (HCV) genotypes 1,3,4,5 and 6. Following approval in 2014, new pharmacokinetics and pharmacodynamics data were reported, which led to important clinical applications. Areas covered: This article reviews the pharmacokinetic and pharmacodynamic properties of the SOF/LDV fixed dose combination for the treatment of HCV...
October 31, 2016: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/27785825/ledipasvir-sofosbuvir-with-or-without-ribavirin-for-the-treatment-of-chronic-hepatitis-c-genotype-1-a-pairwise-meta-analysis
#20
Vinicius L Ferreira, Nayara A Assis Jarek, Fernanda S Tonin, Helena H L Borba, Astrid Wiens, Dominique Araújo Muzzillo, Roberto Pontarolo
BACKGROUND AND AIMS: Ledipasvir with sofosbuvir (LED/SOF) for the treatment of patients infected with genotype 1 hepatitis C virus (HCV) can be used with or without ribavirin (RBV). RBV is well known to promote significant adverse events (AE). The aim of this study was to compare the efficacy and safety of treatment with LED/SOF, with or without RBV, in patients infected with HCV genotype 1. METHODS: We performed a systematic review followed by a pairwise meta-analysis including randomized controlled trials (RCTs) that reported efficacy (rapid virological response (RVR), sustained virological response at 4 and 12 weeks post-treatment (SVR4 and 12), and viral relapse)) and safety outcomes (any AE, serious AE, discontinuation owing to AE, anemia and rash))...
October 27, 2016: Journal of Gastroenterology and Hepatology
keyword
keyword
40094
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"